Mycotic Aortic Aneurysm: A Rare Etiology of Septic Shock
Mycotic aneurysm of the aorta (MAA) is an aortic aneurysm caused by infection. This terminology was first used by Sir William…
Browsing Tag
Shock
CD63 and C3AR1: the molecular targets in the septic shock
Introduction
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection.1 This…
Noxopharm Files Septic Shock Treatment Patent for Veyonda®
SYDNEY - (BUSINESS WIRE) - Australian drug development company Noxopharm Limited (ASX: NOX) in the clinical stage has…
Noxopharm applies to patent Veyonda in septic shock treatment
Australian clinical-stage drug development company Noxopharm (ASX: NOX) announced the filing of an international patent…
Noxopharm (ASX:NOX) submits Veyonda patent for septic shock opportunity
Noxopharm (ASX: NOX) files Veyonda patent for the possibility of septic shock - The Market Herald…
Noxopharm Ltd files patent for Veyonda® as treatment for septic shock
Compelling preclinical COVID-19 data showed that idronoxil, the active ingredient in Veyonda, is effective in stopping cytokines…